Anti-SARS-CoV-1, Spike (Clone COV1-80) -Purified No Carrier Protein

Specificity: COV1-80 targets the prefusion spike protein of SARS-CoV-1 and SARS-CoV-2. Antigen Distribution: Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background: SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. The COV1-80 monoclonal antibody is cross-reactive, targeting the spike protein of both SARS-CoV-1 and SARS-CoV-2. While it does not block the ACE2 receptor, COV1-80 still functions as a neutralizing antibody, meaning it can inhibit the virus's capacity to infect host cells. The exact epitope that COV1-80 binds to remains unidentified, highlighting the need for further research to understand its mechanism of action fully. Nonetheless, the demonstrated neutralizing activity of COV1-80 makes it a promising candidate for therapeutic strategies, particularly in combination therapies that target multiple viral epitopes for enhanced effectiveness.